Literature DB >> 27651368

Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks.

Goodwin G Jinesh1, Sharada Mokkapati2, Keyi Zhu2, Edwin E Morales2.   

Abstract

Pim kinases are being implicated in oncogenic process in various human cancers. Pim kinases primarily deal with three broad categories of functions such as tumorigenesis, protecting cells from apoptotic signals and evading immune attacks. Here in this review, we discuss the regulation of Pim kinases and their expression, and how these kinases defend cancer cells from therapeutic and immune attacks with special emphasis on how Pim kinases maintain their own expression during apoptosis and cellular transformation, defend mitochondria during apoptosis, defend cancer cells from immune attack, defend cancer cells from therapeutic attack, choose localization, self-regulation, activation of oncogenic transcription, metabolic regulation and so on. In addition, we also discuss how Pim kinases contribute to tumorigenesis by regulating cellular transformation and glycolysis to reinforce the importance of Pim kinases in cancer and cancer stem cells.

Entities:  

Keywords:  Blebbishields; CXCR4; Mitochondria; P-glycoprotein; ROS; VEGF

Mesh：

Substances：

Year:  2016        PMID： 27651368     DOI： 10.1007/s10495-016-1289-3

Source DB:  PubMed          Journal:  Apoptosis        ISSN： 1360-8185            Impact factor:   4.677


  21 in total

Review 1.  CaM Kinase: Still Inspiring at 40.

Authors:  K Ulrich Bayer; Howard Schulman
Journal:  Neuron       Date:  2019-08-07       Impact factor: 17.173

Review 2.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

Review 3.  A systematic review on active sites and functions of PIM-1 protein.

Authors:  Youyi Zhao; Aziz Ur Rehman Aziz; Hangyu Zhang; Zhengyao Zhang; Na Li; Bo Liu
Journal:  Hum Cell       Date:  2022-01-09       Impact factor: 4.174

4.  Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.

Authors:  Tatevik R Broutian; Bo Jiang; Jingfeng Li; Keiko Akagi; Shanying Gui; Zhengqiu Zhou; Weihong Xiao; David E Symer; Maura L Gillison
Journal:  Cancer Lett       Date:  2020-01-17       Impact factor: 8.679

5.  Suppressive neutrophils require PIM1 for metabolic fitness and survival during chronic viral infection.

Authors:  Peter J Volberding; Gang Xin; Moujtaba Y Kasmani; Achia Khatun; Ashley K Brown; Christine Nguyen; Jennifer S Stancill; Eli Martinez; John A Corbett; Weiguo Cui
Journal:  Cell Rep       Date:  2021-05-25       Impact factor: 9.995

6.  Exposing the deadly dark side of apoptotic cancer stem cells.

Authors:  Goodwin G Jinesh
Journal:  Oncoscience       Date:  2017-10-23

7.  RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program.

Authors:  Goodwin G Jinesh; Ashish M Kamat
Journal:  Cell Death Discov       Date:  2017-05-29

8.  Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma.

Authors:  Goodwin G Jinesh; Marco Napoli; Marian T Smallin; Andrew Davis; Hayley D Ackerman; Payal Raulji; Nicole Montey; Elsa R Flores; Andrew S Brohl
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.996

9.  Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.

Authors:  Goodwin G Jinesh; Ganiraju C Manyam; Chinedu O Mmeje; Keith A Baggerly; Ashish M Kamat
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

Review 10.  Molecular genetics and cellular events of K-Ras-driven tumorigenesis.

Authors:  G G Jinesh; V Sambandam; S Vijayaraghavan; K Balaji; S Mukherjee
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.